Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study

@inproceedings{Odawara2016OnceweeklyGP,
  title={Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study},
  author={Masato Odawara and Jun-ichiro Miyagawa and Noriyuki Iwamoto and Yasushi Takita and Takeshi Imaoka and Toshinari Takamura},
  booktitle={Diabetes, obesity & metabolism},
  year={2016}
}
AIMS To examine the efficacy and safety of once-weekly dulaglutide 0.75 mg monotherapy compared with once-daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks. METHODS We conducted a phase III, randomized, 52-week (26-week primary endpoint), active- and placebo-controlled trial comparing 492 Japanese patients (dulaglutide, n = 281; liraglutide, n = 141; and placebo, n = 70). Participants and investigators were blinded to treatment assignment for dulaglutide… CONTINUE READING
BETA
6
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes

  • Diabetes therapy : research, treatment and education of diabetes and related disorders
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study

  • Diabetes therapy : research, treatment and education of diabetes and related disorders
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Similar Papers

Loading similar papers…